PROCHÁZKOVÁ, Michaela, Tibor FÜZIK, Danyil GRYBCHUK, Francesco Luca FALGINELLA, Lucie PODEŠVOVÁ, Vyacheslav YURCHENKO, Robert VÁCHA and Pavel PLEVKA. Capsid Structure of Leishmania RNA Virus 1. Journal of Virology. American Society for Microbiology, 2021, vol. 95, No 3, p. "e01957", 12 pp. ISSN 0022-538X. Available from: https://dx.doi.org/10.1128/JVI.01957-20.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Capsid Structure of Leishmania RNA Virus 1
Authors PROCHÁZKOVÁ, Michaela (203 Czech Republic, belonging to the institution), Tibor FÜZIK (703 Slovakia, belonging to the institution), Danyil GRYBCHUK (804 Ukraine, belonging to the institution), Francesco Luca FALGINELLA (380 Italy, belonging to the institution), Lucie PODEŠVOVÁ, Vyacheslav YURCHENKO, Robert VÁCHA (203 Czech Republic, belonging to the institution) and Pavel PLEVKA (203 Czech Republic, guarantor, belonging to the institution).
Edition Journal of Virology, American Society for Microbiology, 2021, 0022-538X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10607 Virology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.549
RIV identification code RIV/00216224:14740/21:00121505
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1128/JVI.01957-20
UT WoS 000609185100014
Keywords in English virus; Leishmania; Viannia; leishmaniasis; parasite; RNA; LRV1; Totiviridae; virion; structure; cryo-electron microscopy; capsid; genome; uncoating; mRNA; CAP-4; decapping
Tags CF BIC, CF CRYO, CF PROT, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 23/5/2022 13:22.
Abstract
Leishmania parasites cause a variety of symptoms, including mucocutaneous leishmaniasis, which results in the destruction of the mucous membranes of the nose, mouth, and throat. The species of Leishmania carrying Leishmania RNA virus 1 (LRV1), from the family Totiviridae, are more likely to cause severe disease and are less sensitive to treatment than those that do not contain the virus. Although the importance of LRV1 for the severity of leishmaniasis was discovered a long time ago, the structure of the virus remained unknown. Here, we present a cryo-electron microscopy reconstruction of the virus-like particle of LRV1 determined to a resolution of 3.65 angstrom. The capsid has icosahedral symmetry and is formed by 120 copies of a capsid protein assembled in asymmetric dimers. RNA genomes of viruses from the family Totiviridae are synthetized, but not capped at the 5' end, by virus RNA polymerases. To protect viral RNAs from degradation, capsid proteins of the L-A totivirus cleave the 5' caps of host mRNAs, creating decoys to overload the cellular RNA quality control system. Capsid proteins of LRV1 form positively charged clefts, which may be the cleavage sites for the 5' cap of Leishmania mRNAs. The putative RNA binding site of LRV1 is distinct from that of the related L-A virus. The structure of the LRV1 capsid enables the rational design of compounds targeting the putative decapping site. Such inhibitors may be developed into a treatment for mucocutaneous leishmaniasis caused by LRV1-positive species of Leishmania. IMPORTANCE Twelve million people worldwide suffer from leishmaniasis, resulting in more than 30 thousand deaths annually. The disease has several variants that differ in their symptoms. The mucocutaneous form, which leads to disintegration of the nasal septum, lips, and palate, is caused predominantly by Leishmania parasites carrying Leishmania RNA virus 1 (LRV1). Here, we present the structure of the LRV1 capsid determined using cryo-electron microscopy. Capsid proteins of a related totivirus, L-A virus, protect viral RNAs from degradation by cleaving the 5' caps of host mRNAs. Capsid proteins of LRV1 may have the same function. We show that the LRV1 capsid contains positively charged clefts that may be sites for the cleavage of mRNAs of Leishmania cells. The structure of the LRV1 capsid enables the rational design of compounds targeting the putative mRNA cleavage site. Such inhibitors may be used as treatments for mucocutaneous leishmaniasis.
Links
LM2015085, research and development projectName: CERIT Scientific Cloud (Acronym: CERIT-SC)
Investor: Ministry of Education, Youth and Sports of the CR, CERIT Scientific Cloud
LM2018127, research and development projectName: Česká infrastruktura pro integrativní strukturní biologii (Acronym: CIISB)
Investor: Ministry of Education, Youth and Sports of the CR
LM2018140, research and development projectName: e-Infrastruktura CZ (Acronym: e-INFRA CZ)
Investor: Ministry of Education, Youth and Sports of the CR
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
3041, interní kód MUName: Structural studies of human and animal pathogens from the order Picornavirales
Investor: EMBO (European Molecular Biology Organization)
90042, large research infrastructuresName: CESNET II
PrintDisplayed: 25/4/2024 09:14